Tech Company Financing Transactions
Aegle Therapeutics Funding Round
Aegle Therapeutics, based in Miami, secured $6.5 million from DeepWork Capital, DEFTA Partners and New World Angels.
Transaction Overview
Company Name
Announced On
10/1/2020
Transaction Type
Venture Equity
Amount
$6,500,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1951 NW 7th Ave. 160 #152
Miami, FL 33136
USA
Miami, FL 33136
USA
Phone
Undisclosed
Website
Email Address
Overview
Aegle Therapeutics Corp. is a first in class, Phase 1/2a ready, biotechnology company isolating extracellular vesicles (EVs) from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa (EB), a rare pediatric connective tissue disorder, and to prevent scarring.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shelley Hartman
Chief Scientific Officer
Evangelos Badiavas
Controller
Patricia Chicvara
VP - Operations
Heidi Kempinski
Browse more venture capital transactions:
Prev: 10/1/2020: Capitalize venture capital transaction
Next: 10/1/2020: Bloomscape venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs